StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Elite Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was $17.53M, down 2.8% year over year. For fiscal 2026 it was $22.82M, up 291.4% from the year before. The highest annual figure on record is $22.82M in fiscal 2026.

Annual free cash flow

PeriodPeriod endValueChange
FY2026Mar 31, 2026$22.82M+291.4%
FY2025Mar 31, 2025$5.83M–
FY2024Mar 31, 2024-$4.04M–
FY2023Mar 31, 2023-$2.40M-139.9%
FY2022Mar 31, 2022$6.01M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$9.26M-36.4%
Q4 FY2026CQ1 2026Mar 31, 2026$8.75M+176.5%
Q3 FY2026CQ4 2025Dec 31, 2025-$5.48M–
Q2 FY2026CQ3 2025Sep 30, 2025$5.00M+266.5%
Q1 FY2026CQ2 2025Jun 30, 2025$14.56M+515.3%
Q4 FY2025CQ1 2025Mar 31, 2025$3.16M+86.6%
Q3 FY2025CQ4 2024Dec 31, 2024-$1.06M-143.7%
Q2 FY2025CQ3 2024Sep 30, 2024$1.36M–
Q1 FY2025CQ2 2024Jun 30, 2024$2.37M–
Q4 FY2024CQ1 2024Mar 31, 2024$1.70M–
Q4 FY2023CQ1 2023Mar 31, 2023$2.43M–
Q3 FY2023CQ4 2022Dec 31, 2022-$568.59K–
Q2 FY2023CQ3 2022Sep 30, 2022-$3.61M–
Q1 FY2023CQ2 2022Jun 30, 2022-$652.11K–

More Elite Pharmaceuticals figures

See a number that looks wrong?